Creabilis Expands Senior Management Team

August 18, 2011

LUXEMBOURG, August 18, 2011 /PRNewswire/ –

Creabilis SA, a clinical stage European biotechnology company addressing
unmet medical needs in dermatology, inflammation and pain, announced today
the expansion of its senior management team with the appointment of three
experienced international pharma executives. Alex Leech joins as Vice
President, Head of Finance and Operations, James Sandy as Senior Vice
President, Head of Development, and Peter Spargo as Senior Vice President
for Chemistry Manufacturing and Controls (CMC).

Alex Leech was most recently Head of Operations at Solace
Pharmaceuticals Inc. Prior to Solace, Alex worked for the Pfizer R&D
organisation where he was Head of European Project Management and worked as
part of a small team leading the restructuring of the company’s drug
development capabilities. Alex has also held a number of operational and
engineering management roles at Ford Motor Company. He holds a BEng in
Mechanical Engineering from University of Sussex and an MBA from Henley
Management College, UK.

James Sandy has over 25 years of pharmaceutical development R&D
experience, most recently at Pfizer as Development Team Leader of Pfizer’s
GI portfolio. During his career, James has held a number of senior
management positions in the pharmaceutical sector and brought several
products to market. James was also Head of Development Operations in Europe
and Asia at Pfizer. Prior to working at Pfizer, James was Head of biometrics
at Astra UK. He holds a BSc in Statistics from University of Sunderland and
MPhil in Statistics & Outcomes Research from Imperial College London.

Dr Peter Spargo has been involved in pharmaceutical research and
development throughout an international career spanning over 22 years. He
was most recently at Novexel as SVP of CMC and played an important role in
the company’s $500m acquisition by AstraZeneca in 2010. Previously, Peter
was Head of Chemical Process R&D for Pfizer in Europe, where he also led a
variety of multi-disciplinary human health development candidate project
teams and was responsible for the company’s Worldwide Pharmaceutical
Sciences Veterinary Medicines portfolio. He holds a PhD from University of
Cambridge.

Dr Eliot Forster CEO of Creabilis said: “This expansion of our senior
management team to complement our current team, reflects Creabilis’ growing
maturity and the confidence we have in our pipeline, our science and the
culture that underpins it. With CT327 having shown positive results in Phase
IIa trials in psoriasis and atopic dermatitis, and other drugs advancing
towards the clinic, we are well positioned to deliver valuable new medicines
for important diseases and value to all our stakeholders. Alex, James and
Peter will play vital roles in ensuring we deliver on that promise.”

About Creabilis SA

Creabilis is a clinical-stage European biotechnology company creating
innovative new drugs to tackle unmet medical needs in dermatology and
inflammatory diseases. Bringing together world class drug development
capabilities and a rich scientific heritage, Creabilis is uniquely
positioned to transform the treatment of its target diseases.

Creabilis’ lead product is CT327 a novel topically applied TrkA kinase
inhibitor developed using the Company’s Low Systemic Exposure (LSE)
technology. CT327 is currently in Phase II clinical trials in psoriasis and
atopic dermatitis and is undergoing proof-of-concept studies in pain. CT340
is a potent TrkA kinase inhibitor under development for the treatment of
conditions in which TrkA kinase inhibition is implicated, including
inflammatory arthritis and pain. The Creabilis portfolio also includes
CT637, a new approach to the treatment of significant inflammatory
conditions, such as rheumatoid arthritis. Earlier-stage projects include a
number of highly promising candidates for dermatological and wider
indications.

Creabilis is backed by some of Europe’s most highly respected life
sciences investors including Sofinnova Partners and Neomed.